Characterization and Outcomes in Patients Treated With Apremilast in Routine Clinical Practice in Spain: Results From the APPRECIATE Study

Background and objectives: It is necessary to expand the knowledge in the use of apremilast in clinical practice. The APPRECIATE study (NCT02740218) aims to describe the characteristics of patients with psoriasis treated with apremilast, to evaluate their perspectives and those of dermatologists, as...

Descripción completa

Detalles Bibliográficos
Autores: Herranz P, Trasobares L, Mateu A, Martínez E, Ruiz-Villaverde R, Baniandrés O, Mataix J, Jiménez-Gómez N, Serra M, Ruiz Genao DP, Rivera N, Tercedor-Sánchez J, Garcia C, Cordey M, Herrera-Acosta E
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2021
País:España
Institución:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
Repositorio:r-FISABIO. Repositorio Institucional de Producción Científica
OAI Identifier:oai:fisabio.fundanetsuite.com:p9936
Acceso en línea:https://fisabio.portalinvestigacion.com/publicaciones/9936
Access Level:acceso abierto
Palabra clave:Apremilast
Psoriasis
Clinical practice
Therapeutic benefits
id ES_e0f8ea9525c38e6cb3e22a17ea3a08bd
oai_identifier_str oai:fisabio.fundanetsuite.com:p9936
network_acronym_str ES
network_name_str España
repository_id_str
spelling Characterization and Outcomes in Patients Treated With Apremilast in Routine Clinical Practice in Spain: Results From the APPRECIATE StudyHerranz PTrasobares LMateu AMartínez ERuiz-Villaverde RBaniandrés OMataix JJiménez-Gómez NSerra MRuiz Genao DPRivera NTercedor-Sánchez JGarcia CCordey MHerrera-Acosta EApremilastPsoriasisClinical practiceTherapeutic benefitsBackground and objectives: It is necessary to expand the knowledge in the use of apremilast in clinical practice. The APPRECIATE study (NCT02740218) aims to describe the characteristics of patients with psoriasis treated with apremilast, to evaluate their perspectives and those of dermatologists, as well as the outcomes obtained in clinical practice in Spain. Methods: Observational, retrospective, cross-sectional, multicenter study of patients with chronic plaque psoriasis who could be contacted 6 (+/- 1) months after apremilast initiation. The data were obtained from medical records and questionnaires from patients and physicians. Results: A total of 80 patients were evaluated; at apremilast onset, they showed mean (standard deviation, SD) Psoriasis Area and Severity Index (PASI) = 8.3 (5.3), mean (SD) Dermatology Life Quality Index (DLQI) = 8.9 (6.6). At six months, 58.8% (n=47) of patients continued apremilast treatment (discontinuations due to lack of efficacy [16.3%], safety/tolerability [20.0%]). In patients continuing treatment, PASI75 was achieved by 36.7% of patients; mean (95% CI) DLQI score was 2.2 (0.7-3.6) and mean (SD) Patient Benefit Index score was 2.8 (0.8). Compliance with physicians' expectations was correlated with benefits reported by patients (r=0.636). Adverse events were reported by 56.3% of patients (the most common were diarrhoea and nausea). Conclusions: Patients receiving apremilast for 6 months in Spanish clinical practice, reported substantial improvements in their quality of life (mean DLQI reduced by more than 6 points) and disease severity (PASI75 achieved by over one-third of patients), despite less skin involvement than patients who enrolled in clinical trials. (C) 2021 AEDV. Published by Elsevier Espana, S.L.U.ELSEVIER ESPANA2021info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://fisabio.portalinvestigacion.com/publicaciones/9936Actas Dermo-SifiliograficasISSN: 00017310ISSNe: 15782190reponame:r-FISABIO. Repositorio Institucional de Producción Científicainstname:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)Españolinfo:eu-repo/semantics/openAccessoai:fisabio.fundanetsuite.com:p99362026-06-11T12:45:17Z
dc.title.none.fl_str_mv Characterization and Outcomes in Patients Treated With Apremilast in Routine Clinical Practice in Spain: Results From the APPRECIATE Study
title Characterization and Outcomes in Patients Treated With Apremilast in Routine Clinical Practice in Spain: Results From the APPRECIATE Study
spellingShingle Characterization and Outcomes in Patients Treated With Apremilast in Routine Clinical Practice in Spain: Results From the APPRECIATE Study
Herranz P
Apremilast
Psoriasis
Clinical practice
Therapeutic benefits
title_short Characterization and Outcomes in Patients Treated With Apremilast in Routine Clinical Practice in Spain: Results From the APPRECIATE Study
title_full Characterization and Outcomes in Patients Treated With Apremilast in Routine Clinical Practice in Spain: Results From the APPRECIATE Study
title_fullStr Characterization and Outcomes in Patients Treated With Apremilast in Routine Clinical Practice in Spain: Results From the APPRECIATE Study
title_full_unstemmed Characterization and Outcomes in Patients Treated With Apremilast in Routine Clinical Practice in Spain: Results From the APPRECIATE Study
title_sort Characterization and Outcomes in Patients Treated With Apremilast in Routine Clinical Practice in Spain: Results From the APPRECIATE Study
dc.creator.none.fl_str_mv Herranz P
Trasobares L
Mateu A
Martínez E
Ruiz-Villaverde R
Baniandrés O
Mataix J
Jiménez-Gómez N
Serra M
Ruiz Genao DP
Rivera N
Tercedor-Sánchez J
Garcia C
Cordey M
Herrera-Acosta E
author Herranz P
author_facet Herranz P
Trasobares L
Mateu A
Martínez E
Ruiz-Villaverde R
Baniandrés O
Mataix J
Jiménez-Gómez N
Serra M
Ruiz Genao DP
Rivera N
Tercedor-Sánchez J
Garcia C
Cordey M
Herrera-Acosta E
author_role author
author2 Trasobares L
Mateu A
Martínez E
Ruiz-Villaverde R
Baniandrés O
Mataix J
Jiménez-Gómez N
Serra M
Ruiz Genao DP
Rivera N
Tercedor-Sánchez J
Garcia C
Cordey M
Herrera-Acosta E
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Apremilast
Psoriasis
Clinical practice
Therapeutic benefits
topic Apremilast
Psoriasis
Clinical practice
Therapeutic benefits
description Background and objectives: It is necessary to expand the knowledge in the use of apremilast in clinical practice. The APPRECIATE study (NCT02740218) aims to describe the characteristics of patients with psoriasis treated with apremilast, to evaluate their perspectives and those of dermatologists, as well as the outcomes obtained in clinical practice in Spain. Methods: Observational, retrospective, cross-sectional, multicenter study of patients with chronic plaque psoriasis who could be contacted 6 (+/- 1) months after apremilast initiation. The data were obtained from medical records and questionnaires from patients and physicians. Results: A total of 80 patients were evaluated; at apremilast onset, they showed mean (standard deviation, SD) Psoriasis Area and Severity Index (PASI) = 8.3 (5.3), mean (SD) Dermatology Life Quality Index (DLQI) = 8.9 (6.6). At six months, 58.8% (n=47) of patients continued apremilast treatment (discontinuations due to lack of efficacy [16.3%], safety/tolerability [20.0%]). In patients continuing treatment, PASI75 was achieved by 36.7% of patients; mean (95% CI) DLQI score was 2.2 (0.7-3.6) and mean (SD) Patient Benefit Index score was 2.8 (0.8). Compliance with physicians' expectations was correlated with benefits reported by patients (r=0.636). Adverse events were reported by 56.3% of patients (the most common were diarrhoea and nausea). Conclusions: Patients receiving apremilast for 6 months in Spanish clinical practice, reported substantial improvements in their quality of life (mean DLQI reduced by more than 6 points) and disease severity (PASI75 achieved by over one-third of patients), despite less skin involvement than patients who enrolled in clinical trials. (C) 2021 AEDV. Published by Elsevier Espana, S.L.U.
publishDate 2021
dc.date.none.fl_str_mv 2021
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://fisabio.portalinvestigacion.com/publicaciones/9936
url https://fisabio.portalinvestigacion.com/publicaciones/9936
dc.language.none.fl_str_mv Español
language_invalid_str_mv Español
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv ELSEVIER ESPANA
publisher.none.fl_str_mv ELSEVIER ESPANA
dc.source.none.fl_str_mv Actas Dermo-Sifiliograficas
ISSN: 00017310
ISSNe: 15782190
reponame:r-FISABIO. Repositorio Institucional de Producción Científica
instname:Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
instname_str Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
reponame_str r-FISABIO. Repositorio Institucional de Producción Científica
collection r-FISABIO. Repositorio Institucional de Producción Científica
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869422251324997632
score 15,812429

Similares en LA Referencia